Literature DB >> 22602835

Incidence of CMV-HCV coinfection in renal transplant recipient.

Avirup Chakraborty1, Krishna Patil, Sanjay Dasgupta, Abhijit Tarafdar, Sekhar Chakrabarti, Nilanjan Chakraborty.   

Abstract

The authors report a case of a 47-year-old cytomegalovirus (CMV) immunoglobulin G (IgG) seropositive male patient with end stage renal disease who received a live renal transplant from a CMV IgG seropositive donor. Six months post-transplantation, the patient presented with reduced renal allograft function associated with fever, severe breathlessness, new onset jaundice and pancytopenia. His CMV DNA PCR came positive. Hepatitis C virus (HCV) RNA PCR also came positive (genotype I) though anti-HCV test performed before and after transplantation was negative. The patient was treated with oral valganciclovir and showed improvement of his clinical condition and was subsequently discharged under supervised therapy. However, the patient could not be treated for HCV because of risk of renal allograft rejection. The authors suggest oral valganciclovir for management of CMV infection and proper detection and eradication of HCV before renal transplantation to avoid future complications and prolongation of allograft survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22602835      PMCID: PMC3339168          DOI: 10.1136/bcr.12.2011.5314

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  38 in total

Review 1.  Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients.

Authors:  F Fabrizi; G Dulai; V Dixit; S Bunnapradist; P Martin
Journal:  Aliment Pharmacol Ther       Date:  2003-12       Impact factor: 8.171

2.  Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients.

Authors:  Kuo-Hsiung Shu; Joung-Liang Lan; Ming-Ju Wu; Chi-Hung Cheng; Chen-Hsu Chen; Wen-Chin Lee; Horng-Rong Chang; Jong-Da Lian
Journal:  Transplantation       Date:  2004-06-27       Impact factor: 4.939

3.  Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group.

Authors:  B J Pereira; S N Natov; B A Bouthot; B V Murthy; R Ruthazer; C H Schmid; A S Levey
Journal:  Kidney Int       Date:  1998-05       Impact factor: 10.612

4.  Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin.

Authors:  Sydney Tang; Ignatius K P Cheng; Vincent K S Leung; Un I Kuok; Anthony W C Tang; Yiu Wing Ho; Kar Neng Lai; Tak Mao Chan
Journal:  J Hepatol       Date:  2003-11       Impact factor: 25.083

Review 5.  Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.

Authors:  Mark W Russo; Craig D Goldsweig; Ira M Jacobson; Robert S Brown
Journal:  Am J Gastroenterol       Date:  2003-07       Impact factor: 10.864

6.  Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy.

Authors:  Seema Baid; Nina Tolkoff-Rubin; Susan Saidman; Raymond Chung; Winfred W Williams; Hugh Auchincloss; Robert B Colvin; Francis L Delmonico; A Benedict Cosimi; Manuel Pascual
Journal:  Am J Transplant       Date:  2003-01       Impact factor: 8.086

7.  Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation.

Authors:  Annette Bruchfeld; Henryk Wilczek; Carl-Gustaf Elinder
Journal:  Transplantation       Date:  2004-09-15       Impact factor: 4.939

8.  Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico.

Authors:  Nahum Méndez-Sánchez; Daniel Motola-Kuba; Norberto C Chavez-Tapia; Jesús Bahena; Ricardo Correa-Rotter; Misael Uribe
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

9.  Evidence of active cytomegalovirus infection and increased production of IL-6 in tissue specimens obtained from patients with inflammatory bowel diseases.

Authors:  Afsar Rahbar; Lennart Boström; Ulla Lagerstedt; Inger Magnusson; Cecilia Söderberg-Naucler; Vivi-Anne Sundqvist
Journal:  Inflamm Bowel Dis       Date:  2003-05       Impact factor: 5.325

10.  Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients.

Authors:  M Durlik; Z Gaciong; D Rowińska; Z Rancewicz; D Lewandowska; B Kozłowska; J Wyzgał; L Soluch; B Walewska-Zielecka; W Rowiński; M Lao
Journal:  Transpl Int       Date:  1998       Impact factor: 3.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.